retatrutide nonalcoholic steatohepatitis nash trial Efficacy and safety of subcutaneous semaglutide once-daily versus placebo in patients with Semaglutide Resolves in Big Placebo-Controlled Triple hormone receptor agonist retatrutide

FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate

July 18, 2025: 1,997 cases are pending in the GLP-1 MDL, which includes lawsuits against Ozempic manufacturer Novo Nordisk

ABSTRACT Background Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes

What should I do if I miss the ibuprofen dose

Preserve the nerve: microsurgical resection of peripheral nerve sheath tumors

The federal court has set up a single Multidistrict Litigation, or MDL 3094: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation, where the court will hear claims regarding injuries caused by Ozempic, Wegovy, Mounjaro, Trulicity and Reybelsus